Retatrutide (LY3437943) is an investigational triple receptor agonist designed to simultaneously engage the GLP-1 receptor, GIP receptor, and glucagon receptor, creating a multi-pathway approach to metabolic regulation. Unlike GLP-1 mono-agonists or GLP-1/GIP dual agonists, Retatrutide’s glucagon receptor activity introduces an additional mechanism for increasing energy expenditure, a feature that has attracted substantial interest in metabolic disease research.

Phase 2 clinical research data for Retatrutide has generated significant scientific interest, reporting substantial body-composition changes observed in pharmacological intervention trials for metabolic research. Studies have examined its effects on adiposity, hepatic steatosis, blood pressure, lipid profiles, and glycemic control in participants with and without type 2 diabetes. Preclinical research continues to examine the mechanistic basis of its triple receptor activity, receptor selectivity profiles, and downstream signaling pathways.

This 20mg concentration supports research protocols requiring larger or extended quantities for preclinical metabolic studies, receptor pharmacology investigations, or in vitro mechanistic research. Retatrutide is a leading compound in triple incretin receptor agonist research and is widely referenced in current metabolic disease literature.

Disclaimer: This product is intended for in vitro research and laboratory use only. It is not intended for human or veterinary use, consumption, or injection. Not approved by the FDA. Not intended to diagnose, treat, cure, or prevent any disease or medical condition. For use by qualified researchers only.